RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:443079

Central serous chorioretinopathy

low confidenceDisorder

Also known as: CSCR

Publications

7,867

Trials

63

Interventional, condition-specific

Researchers

960

Distinct authors in sample

Gene link

—

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare, acquired, choroidal disorder characterized by subretinal detachment in the macular área and leakage of fluid under the retina that accumulates under the central macula. Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity. A blurred or gray spot in the central visual field is common when the retina is detached.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

CSC · central serous retinopathy

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    7,867 matched papers (5,289 in last 10 years) Source

  3. Phenotype characterisedNot found

    No HPO disease–phenotype associations via Monarch for these Mondo IDs

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPresent

    1 FDA · 1 EMA designations (1 FDA orphan-indication approval) — e.g. verteporfin Source

  6. Interventional trialPresent

    63 matched on ClinicalTrials.gov (3 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

2

Designations · 1 with FDA orphan-indication approval

  • FDA verteporfinCentral Serous Chorioretinopathy · 2012-03-09 · Not FDA Approved for Orphan Indication
  • EMA spironolactoneTreatment of central serous chorioretinopathy · 09/01/2026 · PositiveEMA designation

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

1 associated chemical. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • Adrenal Cortex Hormones · marker/mechanism

MyDisease.info · MONDO:0018616

Literature

Is anyone studying this?

7,867

7,867 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

7,867 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

5,289 in the last 10 years · low confidence

Phrase hits: 7,867 · MeSH hits: 91

Open Europe PMC search

Who's working on it?

960

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Chhablani J19 papers · 2026

    Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA, USA.

    Papers in Europe PMC
  2. 02
    Hasan N11 papers · 2026

    Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

    Papers in Europe PMC
  3. 03
    Wu L9 papers · 2026

    Asociados de Macula Vitreo y Retina de Costa Rica, San José, Costa Rica.

    Papers in Europe PMC
  4. 04
    van Dijk EHC8 papers · 2026

    Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.

    Papers in Europe PMC
  5. 05
    Kim M7 papers · 2026

    Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea; Catholic Institute for Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea.

    Papers in Europe PMC
  6. 06
    Vujosevic S7 papers · 2026

    Eye Clinic (C.P., S.V.), IRCCS MultiMedica, Milan, Italy; Department of Biomedical (S.V.), Surgical and Dental Sciences, University of Milan, Milan, Italy.

    Papers in Europe PMC
  7. 07
    Wykoff CC7 papers · 2026

    Retina Consultants of Texas, Retina Consultants of America, Houston, TX, USA.

    Papers in Europe PMC
  8. 08
    Zarnegar A7 papers · 2026

    Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA, USA.

    Papers in Europe PMC
  9. 09
    Boon CJF6 papers · 2026

    Department of Ophthalmology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

    Papers in Europe PMC
  10. 10
    Khurana RN6 papers · 2026

    Northern California Retina Vitreous Associates, Mountain View, CA, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

63

interventional trials for this specific condition

63 interventional trials matched this specific condition name; 3 currently recruiting in our sample.

Data as of 11 September 2026

63 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 97.7th percentile).

low confidence · 97.7th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

63 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

20 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 21 · after dedupe 21 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 21 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (21)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Central serous chorioretinopathy — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Central serous chorioretinopathy" OR "central serous retinopathy"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Central Serous Chorioretinopathy

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Central serous chorioretinopathy" OR "central serous retinopathy"

Interventional trials matched via: both, phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 63 interventional · 20 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: CSCR; CSC

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 2 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (7867) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T16:24:19.395Z